1. Name Of The Medicinal Product
Budelin Novolizer 200 micrograms per actuation inhalation powder
2. Qualitative And Quantitative Composition
Active substance: Budesonide
One delivered dose contains 200 micrograms of budesonide.
Excipient:
10.7 mg of lactose monohydrate/delivered dose
The delivered dose is the dose which is available for the patient after passing the mouthpiece.
3. Pharmaceutical Form
Inhalation powder
White powder
4. Clinical Particulars
4.1 Therapeutic Indications
Regular treatment of persistent asthma.
Note: budesonide is not intended to be used as a reliever of acute asthma.
4.2 Posology And Method Of Administration
Inhalation use
If a patient is switched to Budelin Novolizer 200 micrograms from an alternative inhalation device the dose should be reviewed and adjusted, as necessary, on an individual basis. The active substance, dose regimen and method of delivery should be considered.
Steroid naive patients and patients previously controlled on inhaled steroids:
Adults (including the elderly) and children/adolescents over 12 years of age:
|
|
|
|
Children 6 - 12 years:
|
|
|
|
Children below 6 years of age:
Budelin Novolizer 200 micrograms is not recommended for use in children below age 6 due to insufficient data on safety and efficacy.
Note: For the 200 micrograms doses a 400 micrograms strength is available.
The dose should be adapted to the requirements of each individual, the severity of the disease and the clinical response of the patient. The dose should be adjusted until control is achieved and then should be titrated to the lowest dose at which effective control of asthma is maintained.
Posology limits:
Adults (including the elderly) and children/adolescents over 12 years of age: 200 - 1600 micrograms daily
Children 6 - 12 years: 200 - 800 micrograms daily
Twice daily dosing in children and adults, including the elderly should be used when starting treatment, during periods of severe asthma and while reducing or discontinuing oral glucocorticosteroids.
Once daily dosing up to 800 micrograms may be used in adults, including the elderly and children/adolescents over 12 years of age with mild to moderate asthma already controlled on inhaled glucocorticosteroids (either budesonide or beclometasone dipropionate) administered twice daily.
Once daily dosing up to 400 micrograms may be used in children 6-12 years of age with mild to moderate asthma already controlled on inhaled glucocorticosteroids (either budesonide or beclometasone dipropionate) administered twice daily.
If a patient is transferred from twice daily dosing to once daily dosing this should be at the same equivalent total daily dose (with consideration of the active substance and the method of delivery) and this dose should then be reduced to the minimum dose needed to maintain effective control of asthma. The once daily regimen can be considered only when asthma symptoms are controlled.
In case of once daily dosing this dose should be taken in the evening.
In case of deterioration of asthma control (recognised by e.g. persistent respiratory symptoms, increased use of an inhaled bronchodilator) the dose of inhaled steroids should be increased. Those patients receiving the once daily dose regimen, should be advised to double their dose of inhaled corticosteroid, such that a once daily dose would be administered twice daily. In any case of deterioration of asthma control the patient should seek advice from a medical doctor as soon as possible.
A short acting inhaled beta-2-agonist should be available for the relief of acute symptoms of asthma at all times.
Mode and duration of treatment:
Budelin Novolizer 200 micrograms is intended for long-term therapy. It should be administered regularly according to the recommended schedule even when the patient is asymptomatic.
The improvement in the control of asthma can appear in 24 hours, although 1 - 2 weeks additional treatment period may be necessary to reach a maximum benefit.
In order to ensure that the active substance optimally reaches the intended site of action it is necessary to inhale steadily, deeply and as rapidly as possible (to the maximum inhalation). A clearly audible click and a colour change in the control window from green to redindicates that inhalation has been performed correctly. If an audible click is not heard and there is no colour change in the control window, inhalation should be repeated. The inhaler remains locked until inhalation is performed correctly.
To reduce the risk of oral candidiasis and hoarseness it is recommended that inhalation be performed before meals and that the mouth is rinsed with water or the teeth brushed after each inhalation.
Usage and handling of the powder inhaler (=Novolizer)
Refilling
1. Lightly press together the ribbed surfaces on both sides of the lid, move the lid forwards and lift off.
2. Remove the protective aluminium foil from the cartridge container and take out the new cartridge.
3. Insert the cartridge into the powder inhaler (=Novolizer) with the dosage counter facing the mouthpiece.
4. Replace the lid into the side guides from above and push down flat towards the button until it snaps into place. The cartridge can be left in the powder inhaler (=Novolizer) until it has been used up, or for up to 6 months after insertion.
Note: Budelin Novolizer 200 micrograms cartridges may only be used in the Novolizer powder inhaler
Usage
1. When using the powder inhaler (=Novolizer) always keep it horizontal. First remove the protective cap.
2. Completely depress the coloured button. A loud double click will be heard and the colour of the control window (lower) will change from red to green. Then release the coloured button. The colour green in the window indicates that the powder inhaler (=Novolizer)is ready for use.
3. Exhale as far as possible (but not into the powder inhaler).
4. Put the lips around the mouthpiece. Inhale the powder with a deep breath. During this breath a loud click should be heard, indicating correct inhalation. Hold the breath for a few seconds and then continue with normal breathing.
Note: If the patient needs to take more than 1 actuation at a time, steps 2 - 4 should be repeated.
5. Replace the protective cap on the mouth piece - the dosing procedure is now complete.
6. The number in the top window indicates the number of inhalations left.
Note: The coloured button should only be pressed immediately before inhalation.
A double inhalation in error is not possible with the powder inhaler (=Novolizer). The click sound and the change of colour in the control window indicate that inhalation has been performed correctly. If the colour of the control window does not change then inhalation should be repeated. If inhalation is not completed correctly after several attempts, then the patient should consult the doctor/physician.
Cleaning
The powder inhaler (=Novolizer) should be cleaned at regular intervals, but at least every time the cartridge is changed. Instructions on how to clean the powder inhaler (=Novolizer) can be found in the operating instructions attached.
Note: In order to ensure correct use of the inhaler, patients should receive thorough instructions on how to use the powder inhaler (=Novolizer). Children should only use this product under the supervision of an adult.
4.3 Contraindications
Hypersensitivity to the active substance budesonide or to the excipient lactose monohydrate (which contains small amounts of milk proteins).
4.4 Special Warnings And Precautions For Use
Budesonide is not indicated for treatment of acute dyspnoea or status asthmaticus. These conditions should be treated in the normal way.
Treatment of acute exacerbations of asthma and asthma symptoms may need an increase in the dose of budesonide. The patient should be advised to use a short-acting inhaled bronchodilator as rescue medication to relieve acute asthma symptoms.
Close observation and special care is needed in patients with both active and quiescent pulmonary tuberculosis. Patients with active pulmonary tuberculosis may use budesonide only if they are treated simultaneously with effective tuberculostatics. Similarly patients with fungal, viral or other infections of the airways require close observation and special care and should use budesonide only if they are also receiving adequate treatment for such infections.
Patients who repeatedly fail to perform the inhalation correctly should consult their doctor.
In patients with severe hepatic dysfunction treatment with budesonide - similar to treatment with other glucocorticosteroids - may lead to a reduced elimination rate and an increase in systemic availability. Attention is to be paid to possible systemic effects. Therefore the hypothalamic pituitary adrenocortical (HPA) axis function of these patients should be checked at regular intervals.
Prolonged treatment with high doses of inhaled corticosteroids, particularly higher than the recommended doses, may result in clinically significant adrenal suppression. Additional systemic corticosteroid cover should be considered during periods of stress or elective surgery.
Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). It is important therefore that the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control of asthma is maintained.
It is recommended that the height of children receiving prolonged treatment with inhaled corticosteroids is regularly monitored. If growth is slowed, therapy should be reviewed with the aim of reducing the dose of inhaled corticosteroid, if possible, to the lowest dose at which effective control of asthma is maintained. In addition, consideration should be given to referring the patient to a paediatric respiratory specialist.
Precautions for patients not previously treated with corticosteroids:
When budesonide is used regularly as directed, patients who have previously never or only occasionally received brief treatment with corticosteroids, should experience an improvement in breathing after approximately 1 - 2 weeks. However, extreme mucous congestion and inflammatory processes may obstruct the bronchial passages to such an extent that budesonide cannot fully exert its local effects. In such cases, inhaled therapy with budesonide should be supplemented with a short course of systemic corticosteroids. Inhalation doses are continued after gradually reducing the dose of systemic corticosteroids.
Precautions for switching patients from systemically active corticosteroids to inhalation treatment:
Patients receiving systemic treatment with corticosteroids should be switched to Budelin Novolizer 200 micrograms at a time when their symptoms are under control. In these patients, whose adrenocortical function is usually impaired, systemic treatment with corticosteroids must not be stopped abruptly. At the beginning of the switchover, a high dose of Budelin Novolizer 200 micrograms should be given in addition to the systemic corticosteroids for about 7 to 10 days. Then, depending on the patient's response and depending on the original dose of the systemic steroid, the daily dose of the systemic corticosteroid can be reduced gradually (e.g. 1 milligram prednisolone or the equivalent each week or 2.5 milligram prednisolone or the equivalent each month).The oral steroid should be reduced to the lowest possible level and it may be possible to completely replace the oral steroid with inhaled budesonide.
Within the first few months of switching patients from systemic administration of corticosteroids to inhalation treatment, it may be necessary to resume systemic administration of corticosteroids during periods of stress or in the case of emergencies (e.g. severe infections, injuries, surgery). This applies also to patients who have received prolonged treatment with high doses of inhaled corticosteroids. They may also have impaired adrenocortical function and may need systemic corticosteroid cover during periods of stress.
Recovery from impaired adrenal function may take some considerable time. Hypothalamic pituitary adrenocortical axis function should be monitored regularly.
The patient might feel generally unwell in a non specific way during the withdrawal of systemic corticosteroids despite maintenance or even improvement in respiratory function. The patient should be encouraged to continue with inhaled budesonide and withdrawal of oral steroids unless there are clinical signs which might indicate adrenal insufficiency.
After the patient has been switched to inhalation treatment, symptoms may become manifest that had been suppressed by the previous systemic treatment with glucocorticosteroids, e.g. allergic rhinitis, allergic eczema, muscle and joint pain. Suitable medicinal products should be co-administered to treat these symptoms.
Inhaled budesonide should not be stopped abruptly.
Exacerbation of clinical symptoms due to acute respiratory tract infections:
If clinical symptoms become exacerbated by acute respiratory tract infections, treatment with appropriate antibiotics should be considered. The dose of budesonide can be adjusted as required and, in certain situations, systemic treatment with glucocorticosteroids may be indicated.
If no improvement of symptoms or adequate asthma control is seen within 14 days of treatment, medical advice is sought for either adjusting the dose or clarifying correct inhalation procedure.
Precautions for switching patients from Budelin Novolizer 200 micrograms to Budelin Novolizer 400 micrograms:
Patients who are not able to produce flow rates above 60 l/min and children need careful monitoring when they begin treatment with the same dose but are switched from Budelin Novolizer 200 micrograms to Budelin Novolizer 400 micrograms.
Lactose may contain milk protein. The amount of lactose contained in Budelin Novolizer 200 micrograms does not normally cause problems in lactose intolerant people.
However, in patients with profound enzyme deficiency, lactose intolerance has been reported very rarely following inhalation of powder containing lactose.
4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction
Due to the very low plasma concentration achieved after inhaled dosing, clinically significant drug interactions are in general unlikely.
However, potent inhibitors of CYP3A4 (e.g. ritonavir, itraconazole, ketoconazole, nelfinavir) may markedly increase plasma levels of budesonide. Since data to give dosage recommendations are lacking, the time interval between administration of inhibitors of CYP3A4 and budesonide should be as long as possible and a reduction in the dose of budesonide should be considered.
4.6 Pregnancy And Lactation
Data on approximately 2000 exposed pregnancies indicate no increased teratogenic risk associated with the use of inhaled budesonide.
In animal studies glucocorticoids have been shown to induce malformations (see 5.3). This is not likely to be relevant for humans given recommended doses.
Other types of adverse effects (e.g.intrauterine growth retardation, cardiovascular disease in adulthood) have been identified in animal studies at exposures below the teratogenic dose range.
Budelin Novolizer 200 micrograms should only be used when the expected benefit outweighs the potential risks. The lowest effective dose of budesonide needed to maintain adequate asthma control should be used.
Budesonide is excreted in breast milk. However, at therapeutic doses no effects on the suckling child are anticipated. Budelin Novolizer 200 micrograms can be used during breast feeding.
4.7 Effects On Ability To Drive And Use Machines
No studies on the effects on the ability to drive or use machines have been performed.
4.8 Undesirable Effects
Adverse events are listed below by system organ class and frequency. Frequencies are defined as:
Very common (
|
|
|
|
|
|
|
|
| |||||
|
| |||||
|
|
| ||||
|
|
| ||||
| ||||||
|
|
| ||||
|
|
| ||||
|
| |||||
|
| |||||
|
|
|
|
Mild mucosal irritations accompanied by difficulty in swallowing, hoarseness and cough may commonly occur.
Treatment with inhaled budesonide may result in candida infections in the oropharynx. Experience has shown that candida infection occurs less often when inhalation is performed before meals and/or when the mouth is rinsed after inhalation. In most cases this condition responds to topical anti-fungal therapy without discontinuing treatment with inhaled budesonide.
As with other inhalation therapies, in rare cases paradoxical bronchospasm may occur, manifest by an immediate increase in wheezing after dosing. Paradoxical bronchospasm responds to a fast acting inhaled bronchodilator and should be treated straightaway. Budesonide should be discontinued immediately, the patient should be assessed and, if necessary, alternative treatment instituted.
Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These may include adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma. In long-term treatment growth in children should be monitored regularly.
The susceptibility to infection can be increased. The ability to adapt to stress can be impaired.
Lactose-monohydrate contains small amounts of milk proteins and can therefore cause allergic reactions.
4.9 Overdose
Symptoms of overdose
An acute overdose of Budelin Novolizer 200 micrograms requiring counter-measures is virtually impossible. In the longer term, atrophy of the adrenal cortex can occur. The effects which are usual for glucocorticosteroids, e.g. increased susceptibility to infection, can occur. The ability to adapt to stress can be impaired.
Therapeutic management of overdose
In general, no special emergency treatment is required for acute overdose. When inhalation treatment is continued at the prescribed dosage, the function of the hypothalamic pituitary adrenocortical axis should normalise within about 1 - 2 days.
In stress situations, it may be necessary to administer corticosteroids as a precaution (e.g. high doses of hydrocortisone).
Patients with adrenocortical atrophy are regarded as being steroid-dependent and must be adjusted to the adequate maintenance therapy of a systemic steroid until the condition has stabilised.
5. Pharmacological Properties
5.1 Pharmacodynamic Properties
Pharmacotherapeutic group: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS; Glucocorticoids ATC-Code: R03BA02
Budesonide is a synthetic glucocorticoid. After oral inhalation, it has a local anti-inflammatory effect on the bronchial mucosa.
Budesonide penetrates cellular membranes and binds to a cytoplasmic receptor protein. This complex enters the nucleus and induces there the biosynthesis of specific proteins, like macrocortin (lipocortin). The hormone-like effects occur after a certain latency period (30-60 min) and result in an inhibition of phospholipase A2. It is also possible that therapeutically effective doses of Budesonide (like other anti-inflammatory glucocorticosteroids) suppress cytokine-induced COX-2 expression.
Clinically, the anti-inflammatory effect results e.g. in improvement of the symptoms, such as dyspnoea. The hyperresponsiveness of the bronchial tract to exogenic challenges is reduced.
5.2 Pharmacokinetic Properties
Peak plasma levels appear approximately 30 minutes after inhalation.
Systemic bioavailability after inhalation is up to 37% and the concentration in human plasma after inhalation of a single dose of 1600 micrograms is 0.63 nmol/L. Plasma protein binding is 85-90% and the volume of distribution around 3 l/kg. The elimination half-life from plasma is approximately 2.8 h in adults and markedly lower in children (1.5 h).
The trigger threshold of the powder inhaler (=Novolizer)which must be overcome for successful inhalation is to be found at inspiratory flows through the inhaler of 35 - 50 l/min. Dose linearity for switching from Budesonide Novolizer 200 µg to Budesonide Novolizer 400 µg was shown at flow rates of 60 l/min upwards.
The fine particle dose (particles < 5 µm) measured in vitro in the clinically relevant range is approximately 30 – 50 % related to the nominal dose. In healthy subjects, approximately 20 – 30 % of the metered dose of budesonide pass into the lungs. The remainder deposits in mouth, nose and throat and a large part of it is swallowed. The swallowed portion is subject to a high first-pass effect in the liver. Budesonide is essentially metabolised in the liver via oxidation, catalysed mainly by the enzyme CYP3A4.
The main metabolites are 6β-hydroxybudesonide and 16α-hydroxyprednisolone which show much less pharmacological activity. This limits systemic bioavailability and toxicity.
5.3 Preclinical Safety Data
Preclinical data revealed no special hazard for humans at therapeutic doses based on studies of chronic toxicity, genotoxicity and carcinogenicity.
Glucocorticosteroids, including budesonide, have produced teratogenic effects in animals, including cleft palate and skeletal abnormalities. Similar effects are considered unlikely to occur in humans at therapeutic doses.
6. Pharmaceutical Particulars
6.1 List Of Excipients
Lactose monohydrate
6.2 Incompatibilities
Not applicable
6.3 Shelf Life
• Medicinal product (Budesonide in the cartridge packed in a container)
Shelf life before opening the container
3 years
Shelf life after first opening the container
6 months
• Device ( Powder inhaler=Novolizer)
Shelf life before first use
3 years
In-use shelf life
1 year
To note: The functioning of the powder inhaler (=Novolizer) has been demonstrated in tests for 2000 metered doses. Therefore a maximum of 10 cartridges containing 200 metered doses or 20 cartridges containing 100 metered doses can be used with this device (within a single year) prior to replacement.
6.4 Special Precautions For Storage
Store in the original package. This medicinal product does not require any special temperature storage conditions.
In-Use storage conditions: Keep the Novolizer device tightly closed, in order to protect from moisture.
6.5 Nature And Contents Of Container
1 Polystyrene/polypropylene cartridge containing 100 or 200 metered doses, equivalent to the filling amount of 1.09 g or 2.18 g of powder.
1 Novolizer powder inhaler device (mouthpiece in polycarbonate and powder inhaler in acrylnitrilbutadienestyrol copolymer, polyoxymethylene) packed in a polypropylene container sealed by aluminium foil.
Pack sizes:
Original sales packs:
1 cartridge containing 100/200 metered doses and 1 Novolizer powder inhaler device
2 cartridges containing 200 metered doses each and 1 Novolizer powder inhaler device
Refill packs:
1 cartridge containing 200 metered doses
2 cartridges containing 200 metered doses each
Hospital pack:
(1 cartridge containing 100 metered doses and 1 Novolizer powder inhaler device) x 10
Sample pack:
1 cartridge containing 100 metered doses and 1 Novolizer powder inhaler device
1 cartridge containing 200 metered doses and 1 Novolizer powder inhaler device
“Not all pack sizes may be marketed”
6.6 Special Precautions For Disposal And Other Handling
No special requirements
7. Marketing Authorisation Holder
Meda Pharmaceuticals Ltd
Skyway House
Parsonage Road
Takeley
Bishops Stortford
CM22 6PU, UK
8. Marketing Authorisation Number(S)
PL 15142/0054
9. Date Of First Authorisation/Renewal Of The Authorisation
1 November 2009
10. Date Of Revision Of The Text
30th June 2011
No comments:
Post a Comment